REMARKS

In response to the Restriction Requirement, applicants hereby elect the claims of Group II

(claims 6-9, 26, 27, 29 and 34; drawn to isolated polypeptides) and the polypeptide of SEQ ID

NO: 15. As indicated, for example, in Table 1 (page 14) of the specification, SEQ ID NO: 15 is

encoded by the DNA sequence of SEQ ID NO: 3.

Claims 1-5, 10-24, 30, 32 and 33 have been withdrawn as being drawn to a non-elected

invention. Claim 6 has been amended to remove reference to withdrawn claim 1. Claims 7 and

9 have been amended to remove reference to non-elected sequences. Claims 25, 26, 28, 29, 31

and 34 have been amended to replace reference to claims 7-9 with reference to claims 6-9, and

claim 27 has been amended to correct a typographical error.

It is urged that support for all the above amendments may be found throughout the

specification as originally filed and that none of the amendments constitute new matter. It is

further submitted that the amendments are not being made for reasons of patentability and

therefore do not give rise to prosecution history estoppel.

Applicants hereby reserve the right to rejoin method claims 25, 28 and 35 with the elected

product claims once the product claims are found to be allowable.

Favorable consideration of the amended claims is respectfully requested.

Respectfully submitted,

Janel Geath

Janet Sleath Registration No. 37,007

Date: February 16, 2005

SPECKMAN LAW GROUP PLLC

20601

7